Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. Halozyme Therapeutics Stock PerformanceShares of NASDAQ:HALO opened at $74.94 on Thursday. Get Halozyme Therapeutics alerts:Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Read MoreReceive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.